Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in Luminal A breast cancer

To investigate circadian clocks in human breast tumors, 43 pairs of human samples (tumor and matched normal breast tissues from the same patient) were collected to run bulk-RNAseq, including 29 pairs of Luminal A, 3 pairs of Luminal B, 2 pairs of HER2 and 9 pairs of Triple-negative breast cancer Overall design: Differential genes expression levels and circadian clock time in human normal and paired tumor samples were analysed based on our RNAseq data

为探究人类乳腺肿瘤中的生物钟（circadian clock），本研究收集了43对人类样本（来自同一患者的肿瘤组织与配对正常乳腺组织）用于开展批量RNA测序（bulk-RNAseq），其中涵盖29对管腔A型（Luminal A）、3对管腔B型（Luminal B）、2对HER2型以及9对三阴性乳腺癌（Triple-negative breast cancer）样本。实验设计：基于本研究的RNA测序数据，对人类正常乳腺组织与配对肿瘤组织中的差异基因表达水平及生物钟状态进行了分析。